Jump to content

Eric Vivier

From Wikipedia, the free encyclopedia
Eric Vivier
Born
Scientific career
FieldsImmunology

Eric Vivier is a French professor of immunology at Aix-Marseille and hospital practitioner[1] at Marseille Public University Hospital. He is also Chief Scientific Officer at Innate Pharma,[2] coordinator of the Marseille Immunopôle immunology cluster,[3] and president of the Paris-Saclay Cancer Cluster.[4][5] He has published over 300 scientific articles[6] and serves on the editorial boards of numerous peer-reviewed journals. Vivier is a member of the expert panel of the European Research Council and serves on committees for several pharmaceutical and biotechnology companies.[7][8][9][10]

Early life and education

[edit]

Vivier was born in Clamart, France.[11] He graduated from the Ecole Nationale Vétérinaire de Maisons-Alfort and received his doctoral degree in immunology from Paris XI University.[citation needed] He completed postdoctoral training as a Fogarty International Center Research Fellow at Harvard Medical School with Paul J. Anderson and Stuart F. Schlossman at the Dana-Farber Cancer Institute.[12][13]

Career

[edit]

Vivier joined Aix-Marseille University as a professor at the Centre d'Immunologie de Marseille-Luminy (CIML) in 1993, becoming its director in 2008[14] until 2017.[2] He was one of the four immunologists who co-founded the biotech company Innate-Pharma in 1999.[15] In 2014, he co-founded the Marseille-Immunopole,[16][17][18] an immunology cluster connecting basic research, therapeutic innovation, and industrial development in the Aix-Marseille region.

Vivier became chief scientific officer of Innate Pharma in January 2018. In 2022, he became president of the PSCC (Paris Saclay Cancer Cluster[5][4]), which was designated in December 2022 as the first winner of the "Biocluster" call for expressions of interest under the France 2030 program.[19]

Vivier's research has focused on natural killer (NK) cells and innate lymphoid cells (ILCs).[20][21][22] His work has contributed to the understanding of the development, function, and therapeutic potential of these cells. His early research investigated the mechanism of inhibitory MHC class I receptors on NK cells and the concept of ITIM-bearing molecules. His group also identified the ITAM-bearing polypeptide, KARAP/DAP12/Tyrobp.[23] This research led to the discovery and characterization of ILC3 cells in human and mouse intestines. His contributions have significantly impacted the field of innate immunology.[24][25][26][27]

Awards and honors

[edit]
  • French National League Against Cancer Award (1996, 2004, and 2013)[28]
  • National Award and Tremplins Rhône-Poulenc Award for Biotech start-ups (1999)
  • Lucien Tartois Award from the Fondation pour la Recherche Médicale (1999)[29]
  • Jacques Oudin Award from the French Society for Immunology (2003)[30]
  • Deutsche Gesellschaft für Immunologie/EFIS Award (2004)[31]
  • Grand Prix Turpin in Oncology (2008)[32]
  • Grand Prix Charles Oberling in Oncology (2010)[33]
  • Australasian Society for Immunology, Visiting Speaker Programme Award (2015)
  • Thomson Reuters Highly Cited Researcher (2015, 2016, 2017)[34]

Vivier became a senior fellow of the Institut Universitaire de France in 2007 and was elected to the French National Academy of Medicine in 2013.[citation needed] In 2016, he was awarded honorary citizen of Cassis, Chevalier de la Légion d’Honneur[35] and Ambassadeur de la ville de Marseille.[36]

Current positions

[edit]
  • Professor of Immunology, Marseille Medical School and Assistance-Publique des Hôpitaux de Marseille (PU-PH Classe Exceptionnelle)
  • Head of the “NK cells and Innate Immunity” lab, CIML
  • Head of the NK monitoring lab, Conception Hospital, Marseille
  • Co-founder and coordinator of the Federation Hospitalo-Universitaire Marseille Immunopole
  • Chief Scientific Officer and Senior Vice President of Innate Pharma[2]
  • President of the Paris-Saclay Cancer Cluster

References

[edit]
  1. ^ "Laboratoire d'immunologie - Hôpital de la Conception | AP-HM". fr.ap-hm.fr (in French). Retrieved 2018-01-11.
  2. ^ a b c "Marseille : le Professeur Éric Vivier retrouve Innate Pharma".
  3. ^ "Communauté : Marseille immunopôle". Marseille Immunopôle (in French). Retrieved 2018-01-11.
  4. ^ a b "Innovation | Paris Saclay Cancer Cluster". PSCC (in French). Retrieved 2023-01-10.
  5. ^ a b "Le Paris Saclay cancer cluster veut dynamiser la création de start-up françaises en oncologie". Le journal du Grand Paris - L'actualité du développement de l'Ile-de-France (in French). 2022-08-29. Retrieved 2023-01-10.
  6. ^ "Eric Vivier - Citations Google Scholar". scholar.google.fr. Retrieved 2017-03-14.
  7. ^ "Eric Vivier".
  8. ^ "Steering Committee: Antibodies for Medicine". www.mimabs.org. Retrieved 2017-03-14.
  9. ^ "Comité Scientifique de la Fondation BMS pour la Recherche en Immuno-Oncologie". fondation-bms.fr (in French). Retrieved 2017-03-14.
  10. ^ "Management - Bioaster". Bioaster. Retrieved 2017-03-14.
  11. ^ "Eric Vivier - Who's Who". www.whoswho.fr (in French). Retrieved 2017-03-14.
  12. ^ "Professor Eric Vivier - Centre d'Immunologie de Marseille-Luminy". Walter and Eliza Hall Institute of Medical Research. 2015-01-19. Retrieved 2017-03-14.
  13. ^ "Cancer Immunology Research: 3 (10)". Cancer Immunology Research. 3 (10). 2015-10-01. ISSN 2326-6066.
  14. ^ "APMnews - Le Pr Eric Vivier nommé directeur du Centre d'immunologie Marseille-Luminy". www.apmnews.com (in French). Retrieved 2018-01-11.
  15. ^ "Founders | Innate Pharma". innate-pharma.com. Retrieved 2017-02-16.
  16. ^ "Accueil : Marseille immunopôle". Marseille Immunopôle (in French). Retrieved 2017-02-16.
  17. ^ "Immunopole : l'exception marseillaise". Le Monde.fr (in French). Retrieved 2017-03-14.
  18. ^ "Cancer : la recherche française séduit les industriels étrangers". lesechos.fr. 2016-04-12. Retrieved 2017-03-14.
  19. ^ "France 2030 : « Paris Saclay Cancer Cluster », premier lauréat de l'AMI « Biocluster »". enseignementsup-recherche.gouv.fr (in French). Retrieved 2023-01-10.
  20. ^ "Que suis-je : la philo bouscule la biologie". Le Monde.fr (in French). Retrieved 2017-03-14.
  21. ^ "Une cellule tueuse mutante à l'assaut des virus". Le Monde.fr (in French). Retrieved 2017-03-14.
  22. ^ "Les cellules innées lymphoïdes: système de secours contre les infections de l'intestin". www.inserm.fr (in French). Archived from the original on 2017-03-11. Retrieved 2017-03-14.
  23. ^ Tomasello, Elena; Vivier, Eric (2005-06-01). "KARAP/DAP12/TYROBP: three names and a multiplicity of biological functions". European Journal of Immunology. 35 (6): 1670–1677. doi:10.1002/eji.200425932. ISSN 1521-4141. PMID 15884055. S2CID 45371614.
  24. ^ Huet, Sylvestre. "sciences.blogs.liberation.fr - Une piste pour booster l'immunité ? - Libération.fr". sciences.blogs.liberation.fr (in French). Retrieved 2017-03-14.
  25. ^ "Ces drôles de pieuvres dans notre sang". Le Monde.fr (in French). Retrieved 2017-03-14.
  26. ^ "Les tueuses de l'immunité innée". Pourlascience.fr (in French). Retrieved 2017-03-14.
  27. ^ "Infections: Inactiver un gène pour stimuler le système immunitaire? – Inserm et Science –". 20 January 2012. Retrieved 2017-03-14.
  28. ^ "Prix DUQUESNE 2013 du Comité de Paris de la Ligue Nationale contre le Cancer". www.paca.inserm.fr (in French). Retrieved 2017-03-14.
  29. ^ "Les prix de la fondation pour la recherche médicale" (PDF). Archived from the original (PDF) on 2016-03-03. Retrieved 2017-03-14.
  30. ^ "Société Française d'Immunologie". www.sfi-immunologie.com.fr. Retrieved 2017-03-14.
  31. ^ "EFIS – European Federation of Immunological Societies: EFIS-IL Lecture Award". www.efis.org. Retrieved 2017-03-14.
  32. ^ "Prix René Turpin" (PDF).
  33. ^ "Les membres - Institut Universitaire de France". www.iufrance.fr (in French). Retrieved 2017-03-14.
  34. ^ "Awards" (PDF).
  35. ^ "Eric Vivier est promu dans l'ordre de la Légion d'honneur au grade de chevalier | CIML". www.ciml.univ-mrs.fr. Retrieved 2017-03-14.
  36. ^ "Les ambassadeurs – Accueil – ClubM". clubm.marseille.fr (in French). Retrieved 2017-03-14.
[edit]